Organon Continues Building Women’s Health Portfolio With Forendo Buyout
Executive Summary
The Finnish company’s endometriosis candidate could offer a better safety profile and be the first drug to address disease progression, Organon claims. Q3 revenues declined slightly due to pandemic, generic competition.